Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N02CD07
|
| gptkbp:brand |
gptkb:Emgality
|
| gptkbp:CASNumber |
1807928-93-3
|
| gptkbp:developedBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:drugClass |
gptkb:monoclonal_antibody
|
| gptkbp:form |
gptkb:government_agency
prefilled pen prefilled syringe |
| gptkbp:genericName |
gptkb:galcanezumab
|
| gptkbp:halfLife |
27 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Emgality
|
| gptkbp:indication |
episodic cluster headache
migraine prevention |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:calcitonin_gene-related_peptide_(CGRP)
|
| gptkbp:mechanismOfAction |
CGRP antagonist
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescribes |
adults
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
constipation
hypersensitivity injection site reactions |
| gptkbp:UNII |
7J9QY6B08X
|
| gptkbp:bfsParent |
gptkb:礼来公司
gptkb:Eli_Lilly_and_Company |
| gptkbp:bfsLayer |
5
|